Skip to main content

Targeting cancer vulnerabilities in acute leukemia

Project description

Studying the therapeutic power of 'oncodestroyers'

Most epigenetic-targeting drugs have displayed limited clinical benefits, and key leukaemia drivers remain mostly undruggable. Oncodestroyers (ODs) are small molecule kinase inhibitors combining supreme p53 activation with the selective disruption of multiple leukaemia-specific super-enhancers that drive oncogenes and dependency/vulnerability factors. The EU-funded ONCODESTROYER project will investigate the principles of 'oncodestruction' with the aim of expanding the therapeutic potential of ODs in leukaemia and pre-leukaemia. To that end, it will study OD vulnerability basis, mechanisms of drug action and indicators of therapeutic response in individual patients. Researchers will also explore the translational aspects of OD treatment by identifying OD resistance and relapse mechanisms.

Host institution

THE HEBREW UNIVERSITY OF JERUSALEM
Net EU contribution
€ 3 200 000,00
Address
Edmond J Safra Campus Givat Ram
91904 Jerusalem
Israel

See on map

Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00

Beneficiaries (1)

THE HEBREW UNIVERSITY OF JERUSALEM
Israel
Net EU contribution
€ 3 200 000,00
Address
Edmond J Safra Campus Givat Ram
91904 Jerusalem

See on map

Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00